Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.64 |
| ▸ | XDH | P47989 | 13/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263085 | 0.79 | XDH (0.46) | SLC22A12XDHHTT | |
| SCHEMBL18607199 | 0.79 | XDH (1.00) | SLC22A12XDHCYP2C8CYP2C9 | |
| SCHEMBL1982101 | 0.76 | XDH (0.55) | SLC22A12XDHCSNK2A1FEN1 | |
| SCHEMBL6231017 | 0.76 | XDH (0.45) | SLC22A12XDHDAO | |
| SCHEMBL6235314 | 0.75 | CSNK2A1 (0.43) | SLC22A12XDHCSNK2A1DAO | |
| SCHEMBL19436147 | 0.73 | XDH (0.45) | SLC22A12XDHCSNK2A1 | |
| SCHEMBL20906115 | 0.73 | XDH (0.45) | SLC22A12XDHCSNK2A1HTT | |
| SCHEMBL19436068 | 0.73 | XDH (0.45) | SLC22A12XDHCSNK2A1 | |
| SCHEMBL7668730 | 0.71 | XDH (0.46) | SLC22A12XDHCYP2C8CYP2C9HTT | |
| SCHEMBL6230059 | 0.71 | CDC25B (0.48) | SLC22A12XDHCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | SLC22A12 2207/4885XDH 604/4885CSNK2A1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.